Skip to main content

Simple Voltage Criteria for LVH on ECG

Lvh findings on ecg

Cornell Duration Product in ECG: Detailed, Practical Guide for Clinicians

Left ventricular hypertrophy (LVH) is a key marker of chronic pressure overload and adverse cardiovascular outcomes. Among ECG-based criteria, the Cornell Duration Product (CDP) improves diagnostic accuracy by combining voltage with QRS duration, making it superior to voltage-only criteria in many clinical settings.


Concept and Rationale

Traditional ECG criteria for LVH rely mainly on QRS voltage, which is influenced by body habitus, age, and sex. The Cornell Duration Product incorporates QRS duration, reflecting both myocardial mass and conduction time. This integration enhances sensitivity for detecting true anatomical LVH.


What Is the Cornell Duration Product

The Cornell Duration Product is calculated by multiplying the Cornell voltage by the QRS duration.


Cornell voltage is defined as:

• S wave amplitude in lead V3

• Plus R wave amplitude in lead aVL


Cornell Duration Product = [S(V3) + R(aVL)] × QRS duration (ms)


All voltages are measured in millimeters (mm), and QRS duration is measured in milliseconds (ms), giving a final unit of mm·ms.


Gender Adjustment

Because women typically have lower ECG voltages, a correction is applied:

• Men: use measured S(V3) + R(aVL)

• Women: add 6 mm to the voltage sum before multiplying by QRS duration


Diagnostic Cut-Off

A Cornell Duration Product value:

• > 2440 mm·ms is diagnostic of left ventricular hypertrophy


This cut-off is validated across multiple populations and correlates well with echocardiographic LV mass.


How to Measure Step-by-Step


1. Identify lead V3 and measure the depth of the S wave in millimeters



2. Identify lead aVL and measure the height of the R wave in millimeters



3. Add the two values (apply +6 mm if the patient is female)



4. Measure QRS duration from the earliest onset to the latest offset of the QRS complex in any lead



5. Multiply voltage sum by QRS duration




Clinical Significance

The Cornell Duration Product has several advantages:

• Higher sensitivity than Sokolow–Lyon criteria

• Better correlation with echocardiographic LV mass

• Strong association with cardiovascular morbidity and mortality

• Useful in hypertension, aortic stenosis, and chronic kidney disease


Studies have shown that regression of LVH assessed by Cornell Duration Product during antihypertensive therapy is associated with improved cardiovascular outcomes.


Comparison With Other ECG Criteria

Sokolow–Lyon Criterion

• Based purely on voltage

• High specificity but low sensitivity

• Less reliable in obese and elderly patients


Cornell Voltage Alone

• More sensitive than Sokolow–Lyon

• Still limited by ignoring QRS duration


Cornell Duration Product

• Incorporates both voltage and conduction time

• Best ECG-based predictor of anatomical LVH

• Preferred in research and risk stratification


Limitations

Despite its advantages, Cornell Duration Product has limitations:

• Reduced accuracy in bundle branch block or paced rhythms

• Influenced by myocardial fibrosis and conduction abnormalities

• ECG cannot replace echocardiography or cardiac MRI for definitive LV mass assessment


Exam and Clinical Pearl

When ECG voltage is borderline but QRS duration is prolonged, the Cornell Duration Product can unmask clinically significant LVH that would otherwise be missed.


One-Line Formula for Quick Recall

Cornell Duration Product = [S(V3) + R(aVL)] × QRS duration


This simple calculation adds significant diagnostic value to routine ECG interpretation and should be part of every clinician’s LVH assessment toolkit.



Comments

Popular posts from this blog

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB)

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB) Why this differentiation matters Brugada pattern is a malignant channelopathy associated with sudden cardiac death, while incomplete RBBB is usually a benign conduction variant. Mislabeling Brugada as iRBBB can be fatal; overcalling iRBBB as Brugada can lead to unnecessary anxiety and ICD implantation. --- 1. Basic Definitions Brugada ECG Pattern Primary repolarization abnormality Genetic sodium-channel disorder Characteristic ST-segment elevation in V1–V3 Risk of ventricular fibrillation and sudden death Incomplete RBBB (iRBBB) Depolarization abnormality Delay in right ventricular conduction Common in healthy individuals Usually asymptomatic and benign --- 2. ECG Morphology: Side-by-Side Comparison QRS Duration Brugada: QRS usually <120 ms iRBBB: QRS <120 ms, but with RBBB morphology --- V1–V2 Pattern (Key Differentiator) Brugada Pseudo-RBBB appearance ST elevation ≥2 mm ST segment is coved or saddleback Terminal QRS bl...

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.